Mediator complex subunit 1 mRNA (MED1 mRNA) (MED1 mRNA)

Mediator complex subunit 1 (MED1) mRNA encodes a critical protein component of the Mediator complex, a multi-protein assembly that serves as a bridge between DNA-bound transcription factors and the RNA polymerase II machinery. MED1 is specifically recognized for its role as a coactivator for various nuclear receptors, including the estrogen receptor (ER) and androgen receptor (AR), making it a central regulator of hormone-responsive gene expression (UniProt Q15648). In clinical oncology, MED1 is frequently overexpressed or amplified in breast and prostate cancers, where it drives tumor progression, metastasis, and resistance to endocrine therapies (PubMed: 25103495). Targeting MED1 at the mRNA level using antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs) is an emerging therapeutic strategy aimed at depleting the MED1 protein to disrupt oncogenic transcriptional programs. Beyond its role in cancer, MED1 is involved in adipogenesis and cardiac development, suggesting that systemic inhibition could lead to metabolic or cardiovascular side effects (PubMed: 10406464). Consequently, therapeutic development focuses on achieving tissue-specific delivery or identifying specific mRNA regulatory elements to minimize off-target impacts on normal cellular homeostasis.

Other names

TRAP220 mRNADRIP205 mRNAPBP mRNARB18A mRNAPPAR-binding protein mRNACRSP1 mRNACRSP200 mRNAPPARBP mRNA

Degradation of target mRNA via RNase H-mediated cleavage or the RNA-induced silencing complex (RISC) pathway, resulting in reduced translation of the MED1 protein.